Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. (IVVD) director Ian Sheffield received a grant of stock options for 100,000 shares of common stock on August 31, 2026. The options have an exercise price of $0.9549 per share, expire on August 30, 2036, and are held directly. The grant vests over three years, with one-third vesting on the first anniversary and the remainder vesting in substantially equal monthly installments thereafter, subject to his continuous service. No Rule 10b5-1 trading plan is reported.
Invivyd, Inc. (IVVD) filed an initial statement of beneficial ownership on Form 3 for Sheffield Ian, who is identified as a director of the company. The filing reports no equity transactions or holdings and notes an attached Exhibit 24.1 granting a Power of Attorney.
Invivyd, Inc. (IVVD) reported that Chief Executive Officer Marc Elia received a grant of stock options to purchase 10,700,000 shares of common stock. The options have an exercise price of $0.9645 per share and expire on August 29, 2036. The grant vests over four years, starting August 30, 2026, with 25% vesting on the first anniversary and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued service.
Invivyd, Inc. (IVVD) announced leadership and governance changes and provided an update on its COVID-19 antibody program. The board appointed Chairman Marc Elia as Chief Executive Officer effective August 30, 2026, with CFO William Duke, Jr. continuing as principal financial and accounting officer. Elia’s employment agreement includes a substantial option grant, cash compensation, and change-in-control protections. The board named Ajay Royan Lead Independent Director and added Ian Sheffield as an independent director, who joined the Audit and Compensation Committees. Invivyd also highlighted that its Phase 3 VYD2311 studies, DECLARATION and LIBERTY, are approaching completion, with top-line data from VYD2311 expected around the end of Q3 2026 and potential Biologics License Application filings under either traditional or Accelerated Approval pathways, subject to FDA review.
Invivyd, Inc. (IVVD) reported that Chief Commercial Officer Timothy Edward Lee converted 102,000 restricted stock units into common stock on August 15, 2026, then sold a total of 40,780 common shares in two transactions on August 17–18, 2026. The sales were described as non-discretionary sell-to-cover trades to satisfy tax withholding obligations upon RSU vesting, executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. Reported sale prices are weighted averages across multiple trades within disclosed price ranges.
Invivyd, Inc. (IVVD) reported insider equity transactions by Chief Human Resources Officer Julie Green. On August 15, 2026, 102,000 restricted stock units converted into an equal number of common shares, representing vesting of an RSU award granted February 15, 2025. To satisfy related tax withholding obligations, she then sold 22,355 shares on August 17, 2026 at a weighted-average price of $0.722 per share and 18,425 shares on August 18, 2026 at a weighted-average price of $0.8429, in non-discretionary sell-to-cover transactions executed under a Rule 10b5-1 trading plan adopted February 20, 2025.
Invivyd, Inc. (IVVD) reported that its Chief Financial Officer, William E. Duke, converted 102,000 restricted stock units into an equal number of common shares on August 15, 2026, as part of a scheduled vesting. The underlying RSU award vests in thirds every six months over an eighteen‑month period from February 15, 2025. To cover tax withholding from this vesting, he then sold a total of 40,780 shares of common stock in open-market, non‑discretionary sell‑to‑cover transactions pursuant to a pre‑arranged Rule 10b5‑1 plan adopted on February 20, 2025, at weighted average prices of $0.722 (range $0.682–$0.830) on August 17 and $0.8429 (range $0.760–$0.872) on August 18.
Invivyd, Inc. (IVVD) reported insider equity activity by Chief Legal Officer and Secretary Jill Andersen involving the vesting of 170,000 Restricted Stock Units, each converting into one share of common stock. On August 17, 2026, 37,256 shares of common stock were sold at a weighted average price of $0.722 per share in transactions priced between $0.682 and $0.830. On August 18, 2026, a further 30,706 shares were sold at a weighted average price of $0.8429 per share in transactions priced between $0.760 and $0.872. The sales were described as non-discretionary “sell-to-cover” transactions to satisfy tax withholding obligations upon RSU vesting, conducted under a Rule 10b5-1 plan adopted on February 20, 2025. Following these transactions, an additional 500 shares of common stock are reported as held indirectly by Andersen’s spouse.
Invivyd, Inc. (IVVD) reported insider equity activity by Chief Scientific Officer Robert D. Allen III relating to restricted stock units (RSUs). On August 15, 2026, 102,000 RSUs, each representing one share of common stock, were converted into 102,000 shares of Invivyd common stock as part of an RSU vesting schedule over eighteen months from a February 15, 2025 grant date. In connection with this vesting, Allen executed non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan adopted on February 20, 2025, selling 20,679 shares on August 17, 2026 at a weighted average price of $0.722 and 17,043 shares on August 18, 2026 at a weighted average price of $0.8429 to satisfy tax withholding obligations.
IVVD reports that a holder intends to sell 40,800 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with Nasdaq indicated as the trading market. The shares relate to 102,000 shares of common stock acquired on 08/15/2026 upon vesting of restricted stock units granted under the issuer's 2021 Equity Incentive Plan and characterized as equity compensation.